-
JBCRG-C14(DAHLIA)
NEW
A Multicenter Retrospective Cohort Study Evaluating the Efficacy and Safety of Datopotamab Deruxtecan for Patients with Hormone Receptor-positive HER2 Negative Inoperable or Recurrent Breast Cancer in Japan
- Status
-
Now Recruiting
- Objectives
-
The objective is to evaluate the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in patients with inoperable or recurrent breast cancer in a real-world clinical setting.
- Subjects
-
Hormone receptor-positive, HER2-negative, unresectable or recurrent breast cancer
- Endpoints
-
Primary endpoint
1) Real world progression free survival (rwPFS)
Secondary endpoints
1) Time to next treatment (TTNT)
2) Time to treatment failure (TTF)
3) TTF2
4) rwPFS2
5) Overall survival(OS)
6) Adverse event rate
7) Interstitial lung disease(ILD), Oral mucositis, Time to first occurrence of ocular surface events
8) Relative dose intensity of Dato-DXd
9) Percentage of patients receiving subsequent treatment regimens after Dato-DXd treatment
- Trial Period
-
From Research Approval Date to 31. Dec. 2028
- Lead Principal Investigator
-
Yoichi Naito (General Internal Medicine, National Cancer Center Hospital East)
- Target Sample Size
-
300
- Regimen
-
This is a multicenter, retrospective cohort study designed to collect data on treatment administration, disease progression, and the occurrence of adverse events for all breast cancer patients who began receiving Dato-DXd for the first time between March 19, 2025, and December 31, 2025.
- Source of Funding
-
DAIICHI SANKYO COMPANY, LIMITED
- Conference Presentation
-
- Articles and Publications
-
- UMIN-ID
-
- jRCT
-
jRCT1031250721
- Memo
-
- COI Disclosure
-